Intalight Announces Global HQ Launch in Shanghai and Strategic Collaboration to Advance Core Technologies in AI-Optics Medical Instruments

On November 1, Intalight ushered in a significant moment — the official relocation of its global headquarters to the Shanghai Caohejing Development Zone, along with the establishment of a strategic partnership with the Eye, Ear, Nose, and Throat Hospital affiliated with Fudan University. Leaders and guests from the Xuhui District Government of Shanghai, Lingang Group, Caohejing Development Zone, Shanghai Clinical Innovation and Transformation Research Institute, Shanghai Shenkang Hospital Development Center, Fudan University School of Medicine, the Eye, Ear, Nose, and Throat Hospital affiliated with Fudan University, and the Ninth People's Hospital affiliated with Shanghai Jiaotong University School of Medicine attended the event. Representatives from the investment community, including Linqchuang Lanwan, Qianhai Ark, China Life Insurance, and Aier Eye Hospital, as well as other distinguished guests from various sectors, gathered to witness this milestone. Leveraging the opportunities presented by the new headquarters and collaboration, Intalight is fully advancing the core technology breakthroughs for high-end instruments in “AI + optics,” embarking on a new journey. On the same day, the iDREAMS Intalight Forum · Shanghai was held at the Caohejing Development Zone Conference Center, where renowned global ophthalmology experts convened to discuss cutting-edge trends in ophthalmic diagnosis and treatment technologies.

Leaders from all sectors of society jointly witnessed the lighting ceremony of the signing.

 Group Photo at the Signing Ceremony for Intalight's Global Headquarters Relocation to Caohejing

Mr. Xue Han, Vice General Manager of漕河泾Management Company, and Dr. Li Bing, Co-founder/CEO of赛炜, completed the residency signing. This represents the deep integration of high-end, high-yield intelligent manufacturing, artificial intelligence, and the healthcare industry, marking a key milestone in赛炜's global strategic development.

 Speech by Mr. Wei Zuyan, General Manager of漕河泾Management Company

Mr. Wei Zuye, General Manager of the Caohejing Management Company, welcomed SAIWEI's move-in. In his speech, he pointed out that the Caohejing Development Zone has formed a relatively complete industrial ecosystem in areas such as artificial intelligence and biomedicine. SAIWEI came to Caohejing to establish a research and development center in 2024, and this year, it has further set up its headquarters. The Development Zone focuses on the development of AI+ field industries, promoting in-depth cooperation in the medical-engineering interdisciplinary field with research institutes, universities, and tertiary hospitals. Starting from today's move-in of SAIWEI's headquarters, both parties will further join hands to advance the clinical transformation and application innovation of AI technology.

 Dr. Li Bing, Co-founder of Saiwei, Delivers Welcome Speech

Dr. Li Bing, co-founder of Intalight, pointed out that in the latest "15th Five-Year Plan," technological growth is an absolute priority. The country is comprehensively implementing the AI+ initiative, driving the entire chain of core technology breakthroughs in key areas of high-end instruments, and supporting the development of medical devices. Intalight has been committed to empowering modern optical technology with cutting-edge artificial intelligence, establishing a unique "AI + Optics" technological foundation. Currently, it has launched globally leading products such as the Ruyi Full-Eye OCT, Ruyi Total Corneal Biometer, and Ruyi True Color Camera. Moving forward, relying on the well-established industrial ecosystem of Xuhui Caohejing, the company will continue to expand its presence in the ophthalmic treatment field beyond its existing diagnostic products. Products under development include a full femtosecond laser surgical system and surgical microscopes. Meanwhile, Intalight is actively building an AI-powered ophthalmic healthcare data ecosystem — the Ruyi Center (DREAM CENTER) — to make ophthalmic diagnosis and treatment smarter, more accurate, and more efficient.

Professor Mo Xiaofen, Vice President of the Eye, Ear, Nose and Throat Hospital affiliated with Fudan University, and Dr. Peng Xianzhao, Founder/Chairman of Saiwei, completed a cooperation agreement. Both parties will work together to promote innovative clinical translation and application in ophthalmology, ushering in a new chapter of comprehensive collaboration between medicine and engineering!

Group Photo at the Strategic Cooperation Signing Ceremony between Fudan University Eye, Ear, Nose and Throat Hospital & Intalight

The Ophthalmology Department of the Eye, Ear, Nose, and Throat Hospital affiliated with Fudan University has ranked at the top of the China Hospital Specialty Reputation Rankings for many consecutive years. With its top-tier clinical diagnostic and treatment capabilities, as well as cutting-edge scientific research and innovation strength, it leads the nation in the diagnosis and treatment of complex eye diseases, exploration, and application of advanced ophthalmic technologies. It is a significant hub for ophthalmic medical care, research, and education in China. Previously, as a long-term user of Intalight's full-eye OCT system, the hospital achieved numerous remarkable research results during the initial usage phase. This strategic cooperation aims to focus on the innovative development and clinical translation of new ophthalmic technologies and products through continuous exploration and close collaboration in real clinical settings.

The iDREAMS Saiwei Ruyi Forum focused on two major sections: "International Frontiers · Ruyi OCT Clinical Research and Academic Discussion" and "Ruyi Innovative Technologies and Product Applications." Renowned global ophthalmology experts, including Professor Philip J. Rosenfeld from the Bascom Palmer Eye Institute at the University of Miami in the United States, Professor Kiyoung Kim from Kyung Hee University Medical Center in South Korea, and Professor Sandy Wenting Zhou from Tan Tock Seng Hospital in Singapore, gathered together with many leading ophthalmologists in China.

 Experts from China and abroad share cutting-edge perspectives

The forum focused on discussing the application insights of Intalight's RuYi Full-Eye OCT, RuYi True-Color Camera, and RuYi Full-Cornea Biometer in the ophthalmology field. Dr. Peng Xianzhao, founder/chairman of Intalight, concluded by introducing the company’s cross-disciplinary innovation journey from semiconductors to ophthalmic optics. All participants engaged in forward-looking discussions on cutting-edge technologies and clinical perspectives, jointly mapping out a new blueprint for precise ophthalmic diagnosis and treatment. Experts unanimously agreed that these products demonstrate world-class competitiveness in imaging breadth, depth, speed, and AI-assisted diagnostic accuracy.

Intalight is steadily advancing its global strategic layout. The company's core products have established extensive international influence. Currently, the Intalight Ruyi series has a presence across all seven continents globally, with over 700 installations worldwide and more than 200 SCI papers published. In China, it has covered leading hospitals nationwide. Once expanding overseas, it entered top ophthalmology institutions such as the Bascom Palmer Eye Institute, ranked No.1 in the U.S. for 20 consecutive years, Harvard Medical School, Stanford University, and Moorfields Eye Hospital, the top institution in Europe. This demonstrates that Chinese enterprises' innovation capabilities in high-end medical equipment are gaining widespread recognition in the global academic community.

With the newly completed global headquarters as a strategic cornerstone and top hospital clinical cooperation as an innovation driver, Intalight will deepen the "industry-academia-research-clinical" collaborative innovation model under the guidance of China's "15th Five-Year Plan." Committed to continuous technological breakthroughs and product innovations, Intalight will further integrate artificial intelligence with ophthalmic diagnosis and treatment, leveraging the advantages of the “AI + optics” technology platform to provide more advanced and precise solutions for ophthalmologists and patients worldwide. Light every sight — Intalight will empower modern optics with AI, continuously surpassing limits and illuminating more paths to light!